A better overall survival (OS) for total (ipsilateral) retroperitoneal lipectomy than standard complete resection in patients with retroperitoneal liposarcoma: a comparative multi-institutional study

Cheng-Li Miao¹#, Ling-Ling Zhang²#, William W. Tseng³, Fa-Bo Qiu⁴, Wei-Qi Lu⁵, You-Guo Dai⁶, Xiao-Song Rao⁷, Wen-Jie Li¹, Gao-Kui Zhang⁸, Jun Chen¹, Wen-Qing Liu¹, Xiao-Bing Chen¹, Meng-Meng Xiao¹, Li-Chao Cha⁴, Jiong-Yuan Wang⁵, Yu-Bo Ren⁷, Hao-Yun Yang⁸, Cheng-Hua Luo¹

¹Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, China; ²Department of Oncology, Peking University International Hospital, Beijing, China; ³Department of Surgery, Division of Breast, Endocrine and Soft Tissue Surgery, University of Southern California-Keck School of Medicine, Los Angeles, CA, USA; ⁴Department of Retroperitoneal Tumor Surgery, Affiliated Hospital of Qingdao University, Qingdao, China; ⁵Department of General Surgery, Zhongshan Hospital of Fudan University, Shanghai, China; ⁶Department of Abdominal Surgery, Yunnan Cancer Hospital, Kunming, China; ⁷Department of Pathology, Peking University International Hospital, Beijing, China; ⁸HBR Data Science Ltd., Beijing, China

Contributions: (I) Conception and design: CH Luo, CL Miao; (II) Administrative support: CH Luo; (III) Provision of study materials or patients: CL Miao, L Zhang; (IV) Collection and assembly of data: CL Miao, L Zhang; (V) Data analysis and interpretation: CL Miao, WW Tseng, FB Qiu, WQ Lu, YG Dai, XS Rao, WJ Li, GK Zhang, J Chen, WQ Liu, XB Chen, MM Xiao, LC Cha, JY Wang, YB Ren, HY Yang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Correspondence to: Cheng-Hua Luo, MD, PhD. Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, No.1 Shengming Yuan Road, Zhongguancun Life Science Park, Changping District, Beijing 102206, China. Email: luochenghua@pkuih.edu.cn.

Background: Complete resection (CR) serves as the standard of surgical treatment for retroperitoneal liposarcoma (RPLS). Unfortunately, even at referral centers, recurrence rates are high, and CR may not address multifocal diseases, which are a common phenomenon in RPLS. We sought to retrospectively compare the clinical outcomes of RPLS patients treated with total (ipsilateral) retroperitoneal lipectomy (TRL) and CR. Because TRL remove potentially multifocal tumors in the fat, patients may have a better prognosis than CR.

Methods: Patients with primary/first-recurrent RPLS who had been treated at 5 referral centers were recruited from December 2014 to June 2018. Multivariable Cox regression analyses were conducted to determine the effects of demographic, operative, and clinicopathological variables on the following primary endpoints: local recurrence (LR), local recurrence-free survival (LRFS), and overall survival (OS).

Results: A total of 134 patients were enrolled in this retrospective study, 53 of whom underwent TRL, and 81 of whom underwent CR. The 2 groups were comparable in terms of age, gender, presentation (primary vs. first-recurrent RPLS), number of tumors (unifocal vs. multifocal) at presentation, and Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grade. The TRL group had higher levels of preoperative hemoglobin (Hb) (13 vs. 12.5 g/dL; P=0.008) and a lower amount of intraoperative blood loss (400 vs. 500 mL; P=0.034), but there were no significant differences in the length of hospital stay (23 vs. 22 d; P=0.47) or complications (32 vs. 30; P=0.82) between the 2 groups. In a subset of patients with multifocal tumors at initial presentation, OS was more prolonged in those treated with TRL than those treated with CR (P=0.0272). Based on the multivariable analysis, primary liposarcoma and a low FNCLCC grade were associated with decreased LR and improved OS.

Conclusions: TRL is a safe procedure that positively affects the OS of patients with multifocal RPLS. This novel strategy deserves further investigation in prospective studies.
Introduction

Retroperitoneal sarcoma (RPS) accounts for approximately 0.15% of all adult cancers and has an incidence of 0.5–1 case per 100,000 (1). Retroperitoneal liposarcoma (RPLS) is the most common subtype of RPS. RPLS creates significant challenges for treatment due to its large size and potential for adjacent organ involvement. The role of radiation and systemic therapy in RPLS is not well defined, and surgery is currently the only treatment choice. Macroscopic complete resection (CR) combined with the resection of involved adjacent organs has been recommended for the treatment of RPLS (2-4). CR improves survival more than incomplete resection (R2); however, local recurrence (LR) remains common (40–85%) (3,5-7).

The inability to achieve a true R0 resection with the susceptive microscopic involvement of adjacent organs, structures, and surfaces might contribute to the high rate of postoperative LR in RPLS. Multiple satellite tumor foci may exist in the perceived normal fat that can be separated from the visible tumor as a “field defect” (8). Notably, recurrence not only occurs at the site of resection but also at sites within the retroperitoneum and peritoneal cavity, distant from the resection site (8). This observation has been independently reported by several studies (2,9,10). Singer et al. at the Memorial Sloan Kettering Cancer Center recommend complete surgical resection with abnormal ipsilateral retroperitoneal fat from the diaphragm to the pelvis, including dis-contiguous fat in the independent space. However, Singer et al. only recommend the removal of abnormal retroperitoneal fat and do not provide any supporting evidence for their recommendation (11).

In this study, we propose total (ipsilateral) retroperitoneal lipectomy (TRL), a new concept of surgery for patients with RPLS. TRL involves the total resection of retroperitoneal adipose tissue ipsilateral to the tumor. Under this approach, tumor and ipsilateral fat are always resected en bloc. The contents resected during this procedure include liposarcoma, fat tissue (normal and abnormal), the perirenal fat capsule, and surrounding organs as appropriate, depending on the specific extent of tumor involvement (10).

TRL was first introduced by Dr. Chenghua Luo at Peking University International Hospital (PKUIH) (10). Since 2015, TRL has been implemented at 5 referral centers in China, including PKUIH, the Affiliated Hospital of Qingdao University (AHQU), the Yunnan Cancer Hospital (YCH), Zhongshan Hospital of Fudan University (ZHFU), and University of Southern California-Keck School of Medicine (USC-KSM). Through joint conferences, multidisciplinary therapy team discussions, hands-on courses, and extensive internal communication, this approach has been extensively explored and standardized among these Chinese centers. In this retrospective multicenter study, we tested our scientific hypothesis that TRL is safe and improves the outcomes of RPLS patients compared to conventional CR. We present the following article in accordance with the STROBE reporting checklist (available at https://atm.amegroups.com/article/view/10.21037/atm-22-3332/rc).

Methods

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the institutional review boards of Peking University International Hospital (PKUIH, No. IRB-2021-079), Affiliated Hospital of Qingdao University (AHQU), Yunnan Cancer Hospital (YCH), Zhongshan Hospital of Fudan University (ZHFU), University of Southern California-Keck School of Medicine (USC-KSM). Individual consent for this retrospective analysis was waived. All participating hospitals/institutions were informed and agreed the study. Patients with unilateral primary or first-recurrent RPLS who underwent resection with curative intent between December 2014 and June 2018 were identified from prospectively maintained sarcoma databases at PKUIH, AHQU, YCH, ZHFU, and USC-KSM. Only patients with well-differentiated liposarcoma (WDLPS) or dedifferentiated liposarcoma (DDLPS) who were treated with R0/R1 resection were included in this study. Patients
with central (mesenteric) or primarily pelvic tumors, grossly incomplete (R2) resection, missing clinical information, or a follow-up period of <6 months were excluded from this study. Notably, patients with giant tumors (8) (encompassing ≥6 compartments, as defined by Tseng et al.) were also excluded from this study.

Electronic medical records were retrieved from all 5 institutions to extract data on the following variables: (I) preoperative variables [i.e., age, gender, date of diagnosis, presentation (primary/first-recurrent tumor), symptoms, co-morbidity, hemoglobin (Hb), albumin (ALB), receipt of neoadjuvant therapy, tumor size (maximum diameter), tumor site, number of tumors (unifocal vs. multifocal), and American Society of Anesthesiologists (ASA) score]; (II) intraoperative variables [i.e., type of surgery (TRL vs. CR), organs resected, total period of surgery, and estimated blood loss]; and (III) postoperative variables [i.e., histologic subtype, Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grade (12), length of hospital stay, complications according to Clavien-Dindo classification (13), receipt of adjuvant therapy, dates of LR, and death]. To assess these variables, patients’ medical history, radiologic imaging, operative notes, and pathological reports were reviewed and integrated by experienced multidisciplinary sarcoma specialists at each center. A unifocal tumor was defined as 1 solitary tumor in the retroperitoneum, while multifocal tumors were defined as the presence of 2 or more non-contiguous tumors in the retroperitoneum, as determined by preoperative computed tomography (CT) scans and confirmed by intraoperative findings. Patients who had both WDLPS and DDLPS components in their tumors were classified as DDLPS.

Surgical techniques

CR was defined as the surgical resection of the total tumor mass with grossly negative margins (R0/R1). To achieve this goal, en-bloc resection of the tumor with grossly involved adjacent organs and/or major vessels was carried out. In TRL, in addition to CR, all the ipsilateral retroperitoneal fat was removed. The anatomic extent of lipectomy in TRL was demarcated by the following 6 borders: anterior (the posterior surface of abdominal viscera); posterior (the psoas, iliopsoas, and other muscle surfaces); superior (the diaphragm surface); inferior (the iliac vascular surface); medial [the inferior vena cava surface (to the right) or abdominal aorta surface (to the left)]; and lateral (the lateral abdominal wall surface at mid-auxiliary line level) (see Figure 1).

Follow-up

Postoperative baseline CT/magnetic resonance imaging scans were performed to ensure the complete removal of gross visible fat in all RPLS patients. Patients continued to receive contrast-enhanced CT scans of the abdomen/pelvis every 3 months for 2 years, and then every 6 months for 5 years as recommended by the National Comprehensive Cancer Network (NCCN, United States of America) (14) and The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG) (2). For patients with high-grade DDLPS tumors, contrast-enhanced CT of the chest was added as a form of surveillance imaging.

Statistical analysis

The TRL- and CR-related parameters were compared by independent sample t-tests for the numerical variables and Wilcoxon rank-sum test for the categorical variables. Local recurrence-free survival (LRFS) and overall survival (OS) were defined as the time from the date of surgery to the date of recurrence, or to death/last at follow-up, respectively. LR, LRFS, and OS were identified to determine the safety and oncological outcomes of TRL and CR. Survival curves were obtained by means of Kaplan-Meier plots to estimate the LRFS and OS. The log-rank test was used to compare the survival outcomes. To identify the patient population that would benefit the most from TRL, univariable and multivariable Cox proportional-hazards regression models were used. All the statistical analyses were carried out using SAS software (version 9.4), and a P value <0.05 was considered statistically significant.

Results

In total, 134 patients from 5 referral centers met the inclusion criteria for this study. The number of patients from each center is listed in Table S1. The main characteristics are summarized in Table 1. The patients had a median age of 55 years (range, 29–81 years), and 68 (51%) of the patients were male. Both the TRL and CR groups were comparable in terms of age, gender, and presentation (primary/recurrent). The mean tumor size was 21.0 cm (range, 3.5–45 cm). A total of 60 (45%) patients had multifocal disease (i.e., ≥2 non-contiguous tumors). The mean preoperative Hb was 12.75 g/dL (range, 6.7–16.8 g/dL), and the baseline Hb was higher in the TRL group than the CR group (P=0.008).
Figure 1 TRL. (A) Anterior border: posterior surface of abdominal viscera. (B) Lateral border: surface of lateral abdominal wall at mid-axillary line level. (C) Inferior border: surface of Iliac vessels. (D) Medial border for right RPLS: surface of inferior vena cava. (E) Superior border: surface of diaphragm. (F) Posterior border: surface of psoas, iliopsoas and other muscles. TRL, total (ipsilateral) retroperitoneal lipectomy; RPLS, retroperitoneal liposarcoma.

Table 1 Demographic, operative and clinicopathologic characteristics of RPLS patients

| Variable                              | All patients (n=134) | CR (n=81)  | TRL (n=53) | P value |
|---------------------------------------|----------------------|------------|------------|---------|
| Age, years [range]                    | 55 [29–81]           | 56 [29–81] | 53 [36–77] | 0.890   |
| Gender, n [%]                         | 0.310                | 0.310      | 0.310      |         |
| Male                                  | 68 [51]              | 44 [54]    | 24 [45]    |         |
| Female                                | 66 [49]              | 37 [46]    | 29 [55]    |         |
| Presentation, n [%]                   | 0.120                | 0.120      | 0.120      |         |
| Primary                               | 75 [56]              | 41 [51]    | 34 [64]    |         |
| First recurrence                      | 59 [44]              | 40 [49]    | 19 [36]    |         |
| Tumor size (maximum diameter)*, n [%] | 0.270                | 0.270      | 0.270      |         |
| <21 cm                                | 66 [49]              | 43 [53]    | 23 [43]    |         |
| ≥21 cm                                | 68 [51]              | 38 [47]    | 30 [57]    |         |
| Hemoglobin, g/dL [range]              | 12.75 [6.7–16.8]     | 12.5 [6.7–15.9] | 13 [7.8–16.8] | 0.008 |
| Albumin, g/dL [range]                 | 3.9 [1.7–5.3]        | 3.8 [1.7–4.7] | 4 [2.6–5.3] | 0.070 |
| Neoadjuvant therapy, n [%]            | 9 [7]                | 8 [10]     | 1 [2]      | 0.070 |

Table 1 (continued)
| Variable                              | All patients (n=134) | CR (n=81) | TRL (n=53) | P value |
|---------------------------------------|----------------------|-----------|------------|---------|
| Tumor site, n [%]                    |                      |           |            |         |
| Right retroperitoneum                 | 66 [51]              | 40 [53]   | 26 [49]    | 0.690   |
| Left retroperitoneum                  | 63 [49]              | 36 [47]   | 27 [51]    |         |
| No. of tumors, n [%]                  |                      |           |            | 0.130   |
| Unifocal                              | 74 [55]              | 49 [60]   | 25 [47]    |         |
| Multifocal                            | 60 [45]              | 32 [40]   | 28 [53]    |         |
| Resected organs, n [%]                |                      |           |            | 0.850   |
| None                                  | 53 [40]              | 32 [40]   | 21 [40]    |         |
| 1                                     | 40 [30]              | 25 [31]   | 15 [28]    |         |
| 2                                     | 30 [22]              | 18 [22]   | 12 [23]    |         |
| ≥3                                    | 11 [8]               | 6 [7]     | 5 [9]      |         |
| Operation time, minutes [range]       | 245 [92–689]         | 260 [92–689] | 240 [101–625] | 0.580   |
| Estimated blood loss, mL [range]      | 455 [20–11,000]      | 400 [20–3,000] | 500 [100–11,000] | 0.034   |
| Histologic subtype, n [%]             |                      |           |            | 0.120   |
| Well-differentiated                   | 75 [56]              | 41 [51]   | 34 [64]    |         |
| Dedifferentiated                      | 59 [44]              | 40 [49]   | 19 [36]    |         |
| FNCLCC grade, n [%]                   |                      |           |            | 0.410   |
| Unknown                               | 6 [5]                | 6 [9]     | 0 [0]      |         |
| Grade 1                               | 64 [56]              | 35 [54]   | 29 [58]    |         |
| Grade 2                               | 20 [17]              | 9 [14]    | 11 [22]    |         |
| Grade 3                               | 25 [22]              | 15 [23]   | 10 [20]    |         |
| Complications, n [%]                  | 42 [31]              | 26 [32]   | 16 [30]    | 0.820   |
| Clavien-Dindo classification           |                      |           |            | 0.250   |
| None                                  | 69 [44]              | 41 [51]   | 18 [34]    |         |
| <3                                    | 57 [43]              | 27 [33]   | 30 [57]    |         |
| ≥3                                    | 18 [13]              | 13 [16]   | 5 [9]      |         |
| Adjuvant therapy, n [%]               | 8 [6]                | 6 [7]     | 2 [4]      | 0.390   |
| Length of hospital stay, days [range]  | 23 [3–143]           | 23 [3–143] | 22 [7–45]    | 0.470   |
| Recurrence                            | 51 [38]              | 32 [40]   | 19 [36]    | 0.670   |
| Deceased                              | 17 [13]              | 14 [17]   | 3 [6]      | 0.049   |
| Cause of mortality, n [%]             |                      |           |            | 0.315   |
| Recurrence                            | 12 [9]               | 10 [12]   | 2 [4]      |         |
| Metastasis                            | 5 [4]                | 4 [5]     | 1 [2]      |         |

*, mean/median 21 cm. RPLS, retroperitoneal liposarcoma; CR, complete resection; TRL, total (ipsilateral) retroperitoneal lipectomy; FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer.
No adjacent organs were resected in 40% of the patients; however, 30% of the patients had 1 organ resected, 22% had 2 organs resected, and 8% had ≥3 organs resected. The colon and kidney were the most common organs resected en bloc with the tumor (see Table S2). In the TRL group, an ipsilateral colectomy was performed in 27 (51%) patients and a nephrectomy was performed in 18 (34%) patients. In the CR group, an ipsilateral colectomy was performed in 30 (37%) patients and a nephrectomy was performed in 29 (36%) patients. The Whipple procedure or pancreaticoduodenectomy was performed in 1 patient; and an inferior vena cava resection was performed in 1 patient in the CR group. The tumor site, number of adjacent organs resected, and operative time were comparable between the 2 groups (TRL vs. CR). Overall, 75 (56%) patients had WDLPS, and 59 (44%) had DDLPS. The TRL group tended to have a higher frequency of WDLPS and a lower frequency of DDLPS than the CR group.

**Postoperative morbidity and mortality**

Based on Clavien-Dindo classification (13), fewer patients in the TRL group developed grade-3 or higher complications compared to the CR group (9% vs. 15%). Because of postoperative complications, fewer patients were re-operated on in the TRL group than the CR group (1 vs. 4; see Table S3). The median length of hospital stay was comparable between the TRL and CR groups (22 vs. 23 days; P>0.05). There were no in-hospital deaths in the TRL group; however, 1 patient died in the CR group due to postoperative complications (multi-organ failure).

**LRFS**

Of the 134 RPLS patients, 51 (38%) experienced recurrence at a median follow-up period of 17 months (17 months in the TRL group and 17 months in the CR group). In relation to the recurrent diseases, 28 were locoregional (ipsilateral), 4 were remote (contralateral retroperitoneum), 6 were locoregional + remote, and 13 were unknown. There was no significant difference in LR between the 2 groups (see Figure 2). Recurrence resulted in the death of 12 (9%) patients, but only 2 (16.7%) were from the TRL group, and 10 (83.3%) were from the CR group. Among the patients with multifocal tumors, the 1- and 3-year estimated LRFS rates were 89% [95% confidence interval (CI), 69–96%] and 40% (95% CI, 15–65%) in the TRL group, respectively, and 71% (95% CI, 51–84%) and 39% (95% CI, 19–59%) in the CR group, respectively (see Figure 3). Based on the multivariable analysis, primary presentation was independently associated with a lower risk of LR, while a younger age and FNCLCC grade III were associated with a higher risk of LR (see Table 2).

**OS**

In total, 17 (13%) deaths were recorded during the study period. The major causes of death included postoperative complications in 1 patient, recurrence and/or metastasis in 12 patients, and late complications in 2 patients; the cause of death was unknown in 2 patients. Of the total 17 deaths, 3 patients were in the TRL group, and 14 patients were in the CR group (P=0.049). Only 5 (4%) patients developed...
Table 2 Univariable and multivariable analysis of associations between clinicopathological factors and LR

| Variable                          | Univariable analysis | Multivariable analysis |
|----------------------------------|----------------------|------------------------|
|                                  | HR  | 95% CI      | P value | HR  | 95% CI      | P value |
| **Age, years**                   | 1.03| 1.01–1.06   | 0.0144  | 1.05| 1.02–1.09   | 0.0035  |
| Gender (male vs. female)         | 1.24| 0.71–2.17   | 0.4552  | –   | –           | –       |
| Presentation (primary vs. recurrence) | 0.45| 0.25–0.79   | 0.0057  | 0.35| 0.18–0.70   | 0.0032  |
| CR vs. TRL                       | 2.67| 0.76–9.40   | 0.1262  | –   | –           | –       |
| Hemoglobin, g/dL (≥12.75 vs. <12.75)* | 0.40| 0.14–1.13   | 0.0846  | –   | –           | –       |
| Albumin, g/dL (≥3.9 vs. <3.9)*    | 0.91| 0.52–1.59   | 0.7359  | –   | –           | –       |
| Tumor size, cm (≥21 vs. <21)*    | 1.06| 0.61–1.85   | 0.8301  | –   | –           | –       |
| No. of tumors (unifocal vs. multifocal) | 1.02| 0.59–1.78   | 0.9405  | –   | –           | –       |

| Resected organs                  |                  |                        |
|----------------------------------|------------------|------------------------|
| 1 vs. none                       | 2.07             | 0.99–4.33              | 0.0545  | –   | –           | 0.5220  |
| 2 vs. none                       | 2.79             | 1.32–5.91              | 0.0072  | –   | –           | 0.8679  |
| ≥3 vs. none                      | 2.33             | 0.82–6.64              | 0.1125  | –   | –           | –       |
| Estimated blood loss, mL         | 1.00             | 1.00–1.00              | 0.0004  | 1.00| 1.00–1.00   | 0.0001  |
| FNCLCC grade                     |                  |                        |
| II + III vs. I                   | 2.99             | 1.57–5.69              | 0.0009  | –   | –           | 0.1895  |
| III vs. I + II                   | 3.39             | 1.72–6.71              | 0.0004  | 3.29| 1.66–6.53   | 0.0007  |
| Histologic subtype               |                  |                        |
| WDLPS vs. DDLPS                  | 1.01             | 0.56–1.85              | 0.9632  | –   | –           | –       |
| CD classification (<3 vs. ≥3)    | 0.98             | 0.44–2.19              | 0.9700  | –   | –           | –       |
| Length of hospital stay, days    | 1.01             | 0.99–1.03              | 0.4224  | –   | –           | –       |

*, median value. LR, local recurrence; HR, hazard ratio; CI, confidence interval; CR, complete resection; TRL, total (ipsilateral) retroperitoneal lipectomy; FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer; WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; CD, Clavein-Dindo.

Figure 4 OS according to the unifocality and multifocality of tumors in RPLS patients treated with TRL or CR. TRL was associated with better OS for patients with multifocal tumors than CR (P=0.0272). CR, complete resection; TRL, total (ipsilateral) retroperitoneal lipectomy; OS, overall survival; RPLS, retroperitoneal liposarcoma.

Discussion

Both the extent of the surgical resection and tumor...
Table 3 Univariable and multivariable analysis of association between clinicopathological factors and OS

| Variable                                      | Univariable analysis | Multivariable analysis |
|-----------------------------------------------|----------------------|------------------------|
|                                               | HR       | 95% CI    | P value | HR       | 95% CI    | P value |
| Age, years                                    | 1.03     | 0.99–1.08 | 0.1496  | –        | –         | –       |
| Gender (male vs. female)                      | 1.64     | 0.60–4.52 | 0.3381  | –        | –         | –       |
| Presentation (primary vs. recurrence)         | 0.21     | 0.07–0.66 | 0.0071  | 0.17     | 0.04–0.68 | 0.0122  |
| CR vs. TRL                                    | 2.67     | 0.76–9.40 | 0.1262  | –        | –         | –       |
| Hemoglobin, g/dL (≥12.75 vs. <12.75)*         | 0.40     | 0.14–1.13 | 0.0846  | –        | –         | –       |
| Albumin, g/dL (≥3.9 vs. <3.9)*                 | 0.24     | 0.07–0.82 | 0.0234  | –        | –         | 0.5771  |
| Tumor size, cm (≥21 vs. <21)*                 | 0.89     | 0.34–2.32 | 0.8185  | –        | –         | –       |
| No. of tumors (unifocal vs. multifocal)       | 0.39     | 0.14–1.12 | 0.0793  | –        | –         | –       |
| Resected organs                               |          |           |         |          |           |         |
| 1 vs. none                                    | 3.21     | 0.62–16.61| 0.1649  | –        | –         | –       |
| 2 vs. none                                    | 7.37     | 1.56–34.78| 0.0116  | –        | –         | 0.1478  |
| ≥3 vs. none                                   | 5.78     | 0.81–41.22| 0.0798  | –        | –         | –       |
| Estimated blood loss, mL                      | 1.00     | 1.00–1.00 | <0.0001 | 1.00     | 1.00–1.00 | <0.0001 |
| FNCLCC grade                                  |          |           |         |          |           |         |
| II + III vs. I                               | 6.85     | 1.86–25.22| 0.0038  | –        | –         | 0.1530  |
| III vs. I + II                               | 7.57     | 2.31–24.80| 0.0008  | 6.87     | 2.06–22.93| 0.0017  |
| Histologic subtype                            |          |           |         |          |           |         |
| DDLPS vs. WDLPS                               | 2.35     | 0.70–7.85 | 0.1647  | –        | –         | –       |
| CD classification (<3 vs. ≥3)                 | 0.41     | 0.14–1.17 | 0.0845  | –        | –         | –       |
| Length of hospital stay, days                 | 1.03     | 1.01–1.05 | 0.0008  | –        | –         | 0.1242  |

*, median value. OS, overall survival; HR, hazard ratio; CI, confidence interval; CR, complete resection; TRL, total (ipsilateral) retroperitoneal lipectomy; FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer; DDLPS, dedifferentiated liposarcoma; WDLPS, well-differentiated liposarcoma; CD, Clavein-Dindo.

As far as we know, this is the first study to compare the clinical outcomes of patients with RPLS who were treated with TRL or CR. TRL is a relatively safe procedure compared to CR. In our study, patients who underwent TRL experienced more minor but fewer major or grade ≥3 complications compared to those who underwent CR. In fact, grade ≥3 postoperative morbidity occurred in only 5 (9%) patients in the TRL group, which was remarkably lower than the complication incidence (of approximately 16–21%) reported in recent studies that advocate for extended or compartmental resection (20,21). The amount of estimated intraoperative blood loss was significantly lower in the TRL group than the CR group. During TRL, the dissection of retroperitoneal adipose tissue was...

biology must be taken into account and balanced when treating patients with RPS (15). Clinically, the histologic subtype determines the pattern of recurrence and heavily influences the surgical and management approaches adopted (16). The standard of care for treatment in RPLS is CR; however, CR results in a high rate of recurrence, which requires more extended resection (17-19). Multifocal disease is common in RPLS (8,16). Indeed, multi-foci disease occurs in 34% of patients at initial presentation, and 57% of patients with unifocal disease progress to multifocal disease at recurrence after CR (8). As a newly developed surgical technique, TRL removes thoroughly ipsilateral retroperitoneal adipose tissue en bloc with the tumor. TRL not only achieves complete resection but also attempts to treat multifocal disease while sparing organs rather than liberally resecting them.
carried out from borders with abdominal muscles, visceral organs, and other structures as appropriate. This method decreased the risk of intraoperative injury to blood vessels, which were embedded in adipose tissue. Thus, this technique reduced the amount of blood loss during surgery.

LR and LRFS were not affected by TRL; however, an improvement in OS was observed among patients with multifocal disease who underwent TRL. Multifocal disease has profound effects on the oncological outcomes of RPLS patients (see Table S4). In a recent study, 20% of patients presented with multifocal disease, and the 5-year OS rate was significantly lower in the multifocal group than the unifocal group (8,22-25). In another study, 25% of RPLS patients presented with multifocal disease with curtailed OS (24). In our series, the proportion of multifocal disease at initial presentation was 45% (23% for primary, 22% for first-recurrent RPLS), whereas the 3-year OS rate post-TRL was significantly higher than the 3-year OS rate post-CR in those with multifocal disease (95% CI, 63–97%; P=0.0272). TRL not only improves the OS of patients with multifocal RPLS, but also reduces overall deaths and recurrence- and/or metastasis-related deaths in RPLS patients (P=0.049). Our results suggest that TRL is indicated for multifocal RPLS.

Our study had several limitations. First, due to its retrospective nature, our study had inherent biases. Second, patients with first-recurrent RPLS were included in the data analysis, which might have generated a bias due to the lack of quality control over the original surgery for the primary disease. Third, as the median follow-up period was only 17 months, we could not assess LR, LRFS, and OS over a longer duration. Late recurrences occur after 5 years in RPLS (26). Finally, patient selection for surgical treatment was determined at each center, which introduced an unavoidable selection bias. It would have been more ideal if all 5 centers had jointly determined whether a given patient should undergo TRL or CR. However, ultimately, the critical clinicopathological characteristics were comparable between the 2 groups. Notably, one of the advantages of this study is the relatively low frequency of chemotherapy or radiation therapy in both the neoadjuvant and adjuvant settings; thus, we were able to more accurately compare these 2 surgical approaches with less confounding influence from nonsurgical therapies.

In conclusion, TRL is a relatively safe surgical approach for RPLS patients. Multifocal disease is an important histologic subtype. TRL was associated with a significantly higher OS than CR in this subset of patients. Future prospective studies at sarcoma referral centers with standardized selection criteria for TRL, larger sample sizes, and longer follow-up periods need to be conducted to validate these findings.

**Acknowledgments**

The authors would like to thank Professor Vittorio Quagluiolo and Ferdinando Carlo Maria Cananzi, Sarcoma, Melanoma and Rare Tumors Surgery Unit—Humanitas Clinical and Research Center, Humanitas University, Italy, for their comments and suggestions.

**Funding:** This work was supported by the Beijing Science and Technology Commission (Grant Nos. Z111107067311063 and Z161100000516025), and the Peking University International Hospital Research Fund (No. YN2021ZD04).

**Footnote**

**Reporting Checklist:** The authors have completed the STROBE reporting checklist Available at https://atm.amegroups.com/article/view/10.21037/atm-22-3332/rc

**Data Sharing Statement:** Available at https://atm.amegroups.com/article/view/10.21037/atm-22-3332/dss

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-3332/coif).

GKZ and HYY are from HBR Data Science Ltd. The other authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the institutional review boards of Peking University International Hospital (PKUIH, No. IRB-2021-079), Affiliated Hospital of Qingdao University (AHQU), Yunnan Cancer Hospital (YCH), Zhongshan Hospital of Fudan University (ZHFU) and University of Southern California-Keck School of Medicine (USC-KSM). All participating hospitals/institutions were informed and agreed the study. Individual consent for this retrospective analysis was waived.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. van Houdt WJ, Zaidi S, Messiou C, et al. Treatment of retroperitoneal sarcoma: current standards and new developments. Curr Opin Oncol 2017;29:260-7.
2. Trans-Atlantic RPS Working Group. Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol 2015;22:256-63.
3. Tseng WW, Chen J, Patel D, et al. Multidisciplinary sarcoma tumor board: retroperitoneal liposarcoma. Chin Clin Oncol 2020;9:20.
4. Mansfield SA, Pollock RE, Grignol VP. Surgery for Abdominal Well-Differentiated Liposarcoma. Curr Treat Options Oncol 2018;19:1.
5. Tseng WW, Seo HJ, Pollock RE, et al. Historical perspectives and future directions in the surgical management of retroperitoneal sarcoma. J Surg Oncol 2018;117:7-11.
6. Cananzi FCM, Ruspi L, Sicoli F, et al. Did outcomes improve in retroperitoneal sarcoma surgery? Surg Oncol 2019;28:96-102.
7. Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228:355-65.
8. Tseng WW, Madewell JE, Wei W, et al. Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol 2014;21:2136-43.
9. Loewenstein S, Lubezky N, Nizri E, et al. Adipose-Induced Retroperitoneal Soft Tissue Sarcoma Tumorigenesis: A Potential Crosstalk between Sarcoma and Fat Cells. Mol Cancer Res 2016;14:1254-65.
10. Luo CH. Retroperitoneal Tumors: Clinical management. Springer Netherlands 2018;1:XVII, 276.
11. Singer S, Alektiar K. Treatment Recommendations for Retroperitoneal Liposarcoma. Int J Radiat Oncol Biol Phys 2017;98:271.
12. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathologic prognostic variables and definition of a histopathological grading system. Int J Cancer 1984;33:37-42.
13. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187-96.
14. National Comprehensive Cancer Network. Soft Tissue Sarcoma Version 3.2019 2019, August 16. Available online: https://www.nccn.org/professionals/physician_gls/recently_updated.aspx
15. Jayachandran P, Patel D, Hu J, et al. Multidisciplinary sarcoma tumor board: adolescent and young adult soft tissue sarcoma- myxoid liposarcoma and alveolar soft part sarcoma. Chin Clin Oncol 2020;9:67.
16. Gronchi A, Strauss DC, Miceli R, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. Ann Surg 2016;263:1002-9.
17. Hassan I, Park SZ, Donohue JH, et al. Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience. Ann Surg 2004;239:244-50.
18. Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol 2009;27:24-30.
19. Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol 2009;27:31-7.
20. MacNeill AJ, Gronchi A, Miceli R, et al. Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group. Ann Surg 2018;267:959-64.
21. Wang Z, Wu J, Lv A, et al. Infiltration characteristics and influencing factors of retroperitoneal liposarcoma: Novel evidence for extended surgery and a tumor grading system. Biosci Trends 2018;12:185-92.
22. Carbonne F, Pizzolorusso A, Di Lorenzo G, et al. Multidisciplinary Management of Retroperitoneal Sarcoma: Diagnosis, Prognostic Factors and Treatment. Cancers (Basel) 2021;13:4016.
23. Dehner CA, Hagemann IS, Chriseinger JSA. Retroperitoneal Dedifferentiated Liposarcoma. Am J Clin Pathol 2021;156:920-5.
24. Luo P, Cai W, Yang L, et al. Prognostic significance
of pretreatment lymphocyte/monocyte ratio in retroperitoneal liposarcoma patients after radical resection. Cancer Manag Res 2018;10:4727-34.

25. Luo P, Cai W, Yang L, et al. Retroperitoneal dedifferentiated liposarcoma: Analysis of 61 cases from a large institution. J Cancer 2018;9:3831-8.

26. Tan MC, Brennan MF, Kuk D, et al. Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma. Ann Surg 2016;263:593-600.

(English Language Editor: L. Huleatt)